Dong Wenhui, Kong Ming, Zhu Yuwen, Shao Yang, Wu Dongmei, Lu Jun, Guo Junli, Xu Yong
Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Translational Medicine, Department of Pathophysiology, Nanjing Medical University, Nanjing, China.
Hainan Provincial Key Laboratory for Tropical Cardiovascular Diseases Research and Key Laboratory of Emergency and Trauma of Ministry of Education, Institute of Cardiovascular Research of the First Affiliated Hospital, Hainan Medical University, Haikou, China.
Front Cell Dev Biol. 2020 May 13;8:340. doi: 10.3389/fcell.2020.00340. eCollection 2020.
Liver fibrosis is a complex pathophysiological process to which many different cell types contribute. Endothelial cells play versatile roles in the regulation of liver fibrosis. The underlying epigenetic mechanism is not fully appreciated. In the present study, we investigated the role of BRG1, a chromatin remodeling protein, in the modulation of endothelial cells in response to pro-fibrogenic stimuli and liver fibrosis in mice. We report that depletion of BRG1 by siRNA abrogated TGF-β or hypoxia induced down-regulation of endothelial marker genes and up-regulation of mesenchymal marker genes in cultured endothelial cells. Importantly, endothelial-specific BRG1 deletion attenuated CCl induced liver fibrosis in mice. BRG1 knockdown or BRG1 knockout was accompanied by the down-regulation of TWIST, a key regulator of endothelial phenotype. Mechanistically, BRG1 interacted with and was recruited to the TWIST promoter by HIF-1α to activate TWIST transcription. BRG1 silencing rendered a more repressive chromatin structure surrounding the TWIST promoter likely contributing to TWIST down-regulation. Inhibition of HIF-1α activity dampened liver fibrosis in mice. Similarly, pharmaceutical inhibition of TWIST alleviated liver fibrosis in mice. In conclusion, our data suggest that epigenetic activation of TWIST by BRG1 contributes to the modulation of endothelial phenotype and liver fibrosis. Therefore, targeting the HIF1α-BRG1-TWIST axis may yield novel therapeutic solutions to treat liver fibrosis.
肝纤维化是一个复杂的病理生理过程,多种不同细胞类型均参与其中。内皮细胞在肝纤维化的调控中发挥着多种作用。其潜在的表观遗传机制尚未完全明确。在本研究中,我们探究了染色质重塑蛋白BRG1在调节内皮细胞对促纤维化刺激的反应以及小鼠肝纤维化中的作用。我们报告称,通过小干扰RNA(siRNA)敲低BRG1可消除转化生长因子-β(TGF-β)或缺氧诱导的培养内皮细胞中内皮标志物基因的下调以及间充质标志物基因的上调。重要的是,内皮细胞特异性BRG1缺失可减轻小鼠四氯化碳(CCl)诱导的肝纤维化。BRG1敲低或BRG1基因敲除伴随着内皮细胞表型关键调节因子TWIST的下调。从机制上讲,BRG1与缺氧诱导因子-1α(HIF-1α)相互作用并被招募至TWIST启动子以激活TWIST转录。BRG1沉默使TWIST启动子周围的染色质结构更具抑制性,这可能导致TWIST下调。抑制HIF-1α活性可减轻小鼠肝纤维化。同样,药物抑制TWIST可缓解小鼠肝纤维化。总之,我们的数据表明BRG1对TWIST的表观遗传激活有助于调节内皮细胞表型和肝纤维化。因此,靶向HIF1α-BRG1-TWIST轴可能会产生治疗肝纤维化的新疗法。